Translational Therapeutics

Division of Translational Therapeutics Webpage -051014_html_2eb11b31

Dr. Ran Goldman, Division Head

Dr. Bruce Carleton

Dr. Bruce Carleton, Division Head

Vision

Improve the safety and effectiveness of medication use in children.

Introductory Statement

The Division of Translational Therapeutics is uniquely situated in its ability to provide paediatric care at BC Children’s Hospital site where basic science research, clinical research and clinical practice converge.  This is crucial to the division, as one of our priorities is to successfully bridge the gap between research and clinical practice in order to smoothly translate innovative/next generation tools, therapies and technologies from the research setting into accepted clinical practice. The bedside-to-bench-to-bedside approach we take is especially important within the context of paediatrics because we know less about how children will respond to medication and treatment, than we do about adult populations suffering from similar medical conditions.

Objectives

  • Teaching colleagues, fellows, residents and students about optimizing drug use in children.
  • Providing cutting-edge research that is purpose-built to improve the optimal use of drugs in children using pharmacogenomic, epidemiological and clinical trial methods.
  • Providing clinical service to general paediatrics and subspecialties aimed at finding solutions to drug-related problems.

We are committed to studying and evaluating drug therapies with the goal of improving human health and quality of life, specifically in the areas of drug effectiveness, drug safety and drug policy. We pursue these goals through:

Population Therapeutics and Pharmacoepidemiology – where we focus on medication use and healthcare outcomes using large scale population based data sets to foster pharmaceutical policy innovation through proactive policy, research and knowledge translation concerning the effectiveness, safety and cost management of prescription drugs.

Advanced Methodologies to Discover Effectiveness – Randomized controlled trials, retrospective studies and combination of qualitative and quantitative methods to discover effectiveness of treatments, mostly in acute care paediatrics.

Adverse drug reactions (ADRs) and Pharmacogenomics – using state of the art genotyping and sequencing platforms we identify the genetic determinants of ADRs in paediatric and adult populations. Through our active surveillance approach we are able to collect cases and controls to conduct genetic association and validation studies to define ADR causal genes and to develop diagnostic tests to offer personalized therapeutic recommendations for commonly used drugs.

Dr. Bruce Carleton is the Director of the Pharmaceutical Outcomes Programme (POPi), Director of the PHSA Therapeutic Evaluation Unit, and CEO of the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). He currently leads numerous multi-disciplinary projects relating to drug safety and drug effectiveness. Details regarding these projects can be found here.

Dr. Ran Goldman is the director of Paediatric Research in Emergency Therapeutics (PRETx), which offers an extensive online database of therapeutics research in paediatric acute care. Details regarding PRETx can be found here.

Dr. Mahyar Etminan is a drug safety researcher. He uses large administrative databases and epidemiologic methodologies to quantify rare adverse drug events. Currently, Dr. Etminan is leading a project examining the cardiovascular outcomes of Avastin and Lucentis, two drug therapies used for the treatment of macular degeneration.

Dr. Colin Ross is working to develop safer and more effective medications. A key area of Dr. Ross’s research is focused on the identification of genetic factors that are responsible for individual differences in susceptibility to severe adverse drug reactions in children. Dr. Ross directs a research laboratory with capacity for genomic analyses, including genome sequencing, and functional studies of the effects of genetic variation on drug response.

Do you want to make a difference in paediatrics? If being part of a multi-disciplinary team that pursues excellence in research, and strives to bridge into clinical practice and educational endeavours through innovative strategies, the division of translation therapeutics is the place you want to be.

The Division of Translational Therapeutics is always seeking excellent Graduate Students (M.Sc. & Ph.D.), Post Doctoral Fellows, Clinical Residents and Fellows who are interested in the areas of population therapeutics, pharmacoepidemiology, adverse drug reactions (ADRs) and pharmacogenomics. Training opportunities can be tailored according to needs – ranging from full-time to part-time activities over the course of time required for the research project in question. Trainees are encouraged to contact us with an area of interest or pre-determined projects to pursue with the input and guidance of the division members. All research projects will include participation in grant and protocol development, ethics application submission, publication of manuscripts, presentation of findings, and knowledge translation planning.

As one of the leading research centers in Canada, trainees will be exposed to both the innovative research at BC Children’s Hospital Research Institute and the strong academic environment of the University of British Columbia. In these stimulating and complementary surroundings, trainees will have many opportunities for advancement and interdisciplinary professional development.

Applicants with a background in pharmacogenomics, clinical pharmacology, medical genetics, experimental medicine, paediatrics, pharmacoepidemiology, biostatistics, population health, pharmacy, medical anthropology, ethics or any other related fields are encouraged to contact us.

The Division of Translational Therapeutics provides consultation services to their colleagues at UBC and PHSA affiliated institutions, including: BC Children’s Hospital, Sunny Hill Health Centre, Women’s Hospital, BC Cancer Agency and Vancouver General Hospital. These consultations are primarily complex patient cases addressing drug therapies and/or associated adverse drug reactions (ADRs). In cases where appropriate, the division can provide genotyping and interpretation to provide additional information with regards to therapeutic decisions.

To request a consult from the Division of Translational Therapeutics, please complete the following form and other associated information to peds.tt@cfri.ubc.ca.

Publications

1. Goldman RD. Acetaminophen in children: An old drug with new warnings. Can Fam Physician. 2013;59(10):1065-6.
http://www.ncbi.nlm.nih.gov/pubmed/24130280

2. Chin B, Chan ES, Goldman RD. Early exposure to food and food allergy in children. Can Fam Physician. 2014;60(4):338-9
http://www.ncbi.nlm.nih.gov/pubmed/24733323

3. Matejcek A, Goldman RD. Treatment and prevention of ophthalmia neonatorum. Can Fam Physician. 2013;59(11):1187-90.
http://www.ncbi.nlm.nih.gov/pubmed/24235191

4. Goldman RD. Caffeinated energy drinks in children. Can Fam Physician. 2013;59(9):947-8.
http://www.ncbi.nlm.nih.gov/pubmed/24029508

5. Camp PG, Norton SP, Goldman RD, Shajari S, Smith A, Heathcote S, Carleton B. Emergency Department Visits for Children with Acute Asthma: Discharge Instructions, Parental Plans and Follow Through of Care – A Prospective Study. CJEM. 2013;15(0):1-10
http://www.ncbi.nlm.nih.gov/pubmed/24192509

6. Goldman RD. Bismuth salicylate for diarrhea in children. Can Fam Physician. 2013;59(8):843-4.
http://www.ncbi.nlm.nih.gov/pubmed/23946025

7. Goldman RD. Acute treatment of anaphylaxis in children. Can Fam Physician. 2013;59(7):740-1.
http://www.ncbi.nlm.nih.gov/pubmed/23851537

8. Chan M, Goldman RD. Erythema multiforme in children: the steroid debate. Can Fam Physician. 2013;59(6):635-6.
http://www.ncbi.nlm.nih.gov/pubmed/23766045

9. Goldman RD. Pacifier use in the first month of life. Can Fam Physician. 2013;59(5):499-500.
http://www.ncbi.nlm.nih.gov/pubmed/23673585

10. Goldman RD. L'acetaminophene chez les enfants: Ancien medicament, nouveaux avertissements. Can Fam Physician. 2013;59(10):e449-50.
http://www.ncbi.nlm.nih.gov/pubmed/24130280

11. Goldman RD, Mounstephen W, Kirby-Allen M, Friedman JN. Intravenous Magnesium Sulfate for Vaso-occlusive Episodes in Sickle Cell Disease. Paediatrics. 2013;132:e1634-41
http://www.ncbi.nlm.nih.gov/pubmed/24276838

12. Goldman RD. Zinc supplementation for acute gastroenteritis. Can Fam Physician. 2013;59(4):363-4.
http://www.ncbi.nlm.nih.gov/pubmed/23585601

13. Tan E, Smith CH, Goldman RD. Antidepressants for functional gastrointestinal disorders in children. Can Fam Physician. 2013;59(3):263-4.
http://www.ncbi.nlm.nih.gov/pubmed/23486795

14. Smith CH, Israel DM, Schreiber R, Goldman RD. Proton pump inhibitors for irritable infants. Can Fam Physician. 2013;59(2):153-6.
http://www.ncbi.nlm.nih.gov/pubmed/23418240

15. Goldman RD. Child health update: estrogen cream for labial adhesion in girls. Can Fam Physician. 2013;59(1):37-8.
http://www.ncbi.nlm.nih.gov/pubmed/23341655

16. Smith CH, Goldman RD. Staphylococcus aureus decolonization for recurrent skin and soft tissue infections in children. Can Fam Physician. 2012;58(12):1350-2.
http://www.ncbi.nlm.nih.gov/pubmed/23242892

17. McWilliams CJ, Smith CH, Goldman RD. Acute otitis externa in children. Can Fam Physician;58(11):1222-4.
http://www.ncbi.nlm.nih.gov/pubmed/23152458

18. Mark Cicero, Linda Brown, Frank Overly, Jorge Yarzebski, Garth Meckler, Susan Fuchs, Sarita Chung, Andrew Garrett, Daniel Fagbuyi, Kathleen Adelgais, Ran D. Goldman, James Parker, Marc Auerbach, Antonio Riera, David Cone and Carl Baum. Creation and Delphi- Method Refinement of Prehospital Paediatric Disaster Triage Simulations. Prehospital Emergency Care. In Press.

1. Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder SJ, Hayden M, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Ped Blood Cancer. 2014 Jun;61(6):1055-62.
http://www.ncbi.nlm.nih.gov/pubmed/24474498

2. Rieder MJ, Carleton BC. Pharmacogenomics and adverse drug reactions in children. Front Genet. 2014 April;5:78.
http://www.ncbi.nlm.nih.gov/pubmed/24795743

3. Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC, the CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014 Apr;55(4):496-506.
http://www.ncbi.nlm.nih.gov/pubmed/24597466

4. Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC, Recommendations Group CC. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol. 2013 Nov; 20(3): e369-e396.
http://www.ncbi.nlm.nih.gov/pubmed/24214521

5. Camp PG, Norton S, Goldman R, Shajari S, Smith MA, Heathcote S, Carleton BC. Emergency Department visits for children with acute asthma: Discharge instructions, parental plans and follow through of care – A prospective study. CJEM. 2013;15(0):1-10.
http://www.ncbi.nlm.nih.gov/pubmed/24192509

6. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Feroz-Zada Y, Dube MP, Carleton BC, Hayden MR; CPNDS Consortium. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013 Aug;94(2):243-51.
http://www.ncbi.nlm.nih.gov/pubmed/23588304

7. Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; the CPNDS Consortium. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81.
http://www.ncbi.nlm.nih.gov/pubmed/23441093

8. Amstutz U, Ross CJD, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC. HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013 Jul;94(1):142-9.
http://www.ncbi.nlm.nih.gov/pubmed/23588310

9. Zhang T, Smith MA, Camp PG, Carleton BC. High use of health services in patients with suboptimal asthma drug regimens: A population-based assessment in British Columbia, Canada. Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):744-51.
http://www.ncbi.nlm.nih.gov/pubmed/23559540

10. Dionne F, Mitton C, Rassekh R, Brooks B, Ross CJ, Hayden MR, Carleton BC. Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics J. 2012 Jun;12(3):205-13.
http://www.ncbi.nlm.nih.gov/pubmed/21502965

11. Shaw K, Amstutz U, Jimenez-Mendez R, Ross CJ, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther Drug Monit. 2012 Apr;34(2):121-3.
http://www.ncbi.nlm.nih.gov/pubmed/22406651

12. Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer MLA, Nauta M, Carleton BC, Koren G, Hayden MR. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.  Clin Pharmacol Ther. 2012 Apr;91(4):692-9.
http://www.ncbi.nlm.nih.gov/pubmed/22398969

13. Shaw K, Amstutz U, Carleton BC. Using pharmacogenetics to understand adverse drug reactions in children. Paediatric Child Health. 2011 Nov;16(9):537-8 PMID: 23115490

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223886/

14. Amstutz U, Carleton BC. Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther. 2011 Jun;89(6):924-7.
http://www.ncbi.nlm.nih.gov/pubmed/21508939

15. Carleton BC. Demonstrating utility of pharmacogenetics in paediatric populations: methodological considerations. Clin Pharmacol Ther. 2010 Dec;88(6):757-9.
http://www.ncbi.nlm.nih.gov/pubmed/21081946

16. Loo TT, Ross CJD, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC. Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmacogenomics. 2010 Sep;11(9):1269-85.

http://www.ncbi.nlm.nih.gov/pubmed/20860467

17. Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid. 2010 Jul;20(7):681-7
http://www.ncbi.nlm.nih.gov/pubmed/20578893

18. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; the CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009 Dec;41(12):1345-9.
http://www.ncbi.nlm.nih.gov/pubmed/19898482

19. Carleton BC, Poole RL, Smith MA, Leeder JS, Ghannadan R, Ross CJD, Philips MS, Hayden MR. Adverse drug reaction active surveillance: developing a national network in Canada’s children’s hospitals. Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):713-21.
http://www.ncbi.nlm.nih.gov/pubmed/19507171

20. Zhang T, Carleton BC, Prosser RJ, Smith MA. The added burden of comorbidity in patients with asthma. J Asthma. 2009 Dec;46(10):1021-6.
http://www.ncbi.nlm.nih.gov/pubmed/19995140

1. Mukonzo J, Owen J, Ogwal-Okeng J, Kuteesa, R, Nanzigu S, Sewankambo N, Thabane L, Gustafsson L, Ross CJD, Aklillu E. Pharmacogenetic based Efavirenz dose modification: Suggestions for an African population and the different CYP2B6 genotypes. PLOS ONE. 2014 Jan 31;9(1)e86919.
http://www.ncbi.nlm.nih.gov/pubmed/24497997 (SA)

2. Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Hayden MR, Ross CJD, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Paediatric Blood & Cancer. 2014 Jun;61(6):1055-62.
http://www.ncbi.nlm.nih.gov/pubmed/24474498 (SA)

3. Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ. The emerging era of pharmacogenomics: Current successes, future potential, and challenges. Clin Genet. 2014 Jul;86(1):21-8.
http://www.ncbi.nlm.nih.gov/pubmed/24684508

4. Visscher H, Ross CJD, Rassekh SR, Sandor G, Caron HN, van Dalen EC, Kremer LC, van der Pal J, Rogers PC, Rieder MJ, Carleton BC, Hayden MR & the CPNDS consortium. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Paediatric Blood & Cancer. 2013 Aug;60(8):1375-81.
http://www.ncbi.nlm.nih.gov/pubmed/23441093 (FA/SA)

5. Pussegoda K, Ross CJD, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Carleton BC, Hayden MR & the CPNDS Consortium. Replication of TPMT genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol & Therapeutics . 2013 Aug; 94(2):243-51.
http://www.ncbi.nlm.nih.gov/pubmed/23588304 (FA/SA)

6. Amstutz U, Ross CJD, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC; CPNDS Consortium. HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013 Jul;94(1):142-9.
http://www.ncbi.nlm.nih.gov/pubmed/23588310 (FA/SA)

7. Sistonen J, Madadi P, Ross CJD, Yazdanpanah M, Lee J, Landsmeer M, Nauta M, Carleton BC, Koren G, Hayden MR. Prediction of opioid toxicity in neonates and their mothers using a novel combination of genetic markers. Clinical Pharmacology & Therapeutics. 2012 Apr;91(4):692-9.
http://www.ncbi.nlm.nih.gov/pubmed/22398969 (FA/SA)

8. Shaw K, Amstutz U, Jimenez-Mendez R, Ross CJD, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Therapeutic Drug Monitoring. 2012 Apr;34(2):121-3.
http://www.ncbi.nlm.nih.gov/pubmed/22406651 (SA)

9. Visscher H, Ross CJD, Rassekh R, Barhdadi A, Dubé MP, al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AMK, Rogers PC, Phillips MS, Rieder M, Carleton BC, Hayden MR, & the CPNDS consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Journal of Clinical Oncology. 30:1422-1428, 2012.
http://www.ncbi.nlm.nih.gov/pubmed/21900104 (FA/SA)

10. Ross CJD, Visscher H, Rassekh SR, Castro-Pastrana L, Shereck E, Carleton BC, Hayden MR. Pharmacogenomics of serious adverse drug reactions in paediatric oncology. Journal of Population Therapeutics and Clinical Pharmacology. J Popul Ther Clin Pharmacol. 2011;18:e134-51.
http://www.ncbi.nlm.nih.gov/pubmed/21467604 (FA)

11. Ross CJD, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC and Hayden MR and the CPNDS Consortium. The Canadian Pharmacogenomics Network for Drug Safety - A model for safety pharmacology. Thyroid. 2010 Jul;20(7):681-7.
http://www.ncbi.nlm.nih.gov/pubmed/20578893 (FA)

12. Madadi P, Ross CJD, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: A case–control study. Clinical Pharmacology & Therapeutics. 2009 Jan;85(1):31-5.
http://www.ncbi.nlm.nih.gov/pubmed/18719619 (FA/SA)

13. Visscher H, Ross CJD, Dubé MP, Carleton B, Hayden MR. Application of principal component analysis to pharmacogenomic studies in Canada. J Pharmacogenomics. 2009 Dec;9(6):362-72.
http://www.ncbi.nlm.nih.gov/pubmed/19652663 (FA/SA)

14. Ross CJD, Katzov-Eckert H, Dubé MP, Brook B, Rassekh SR, Barhdadi A, Feroz-Zadac Y, Visscher H, Brown AMK, Rogers PC, Phillips MS, Carleton B, Hayden MR. TPMT and COMT genetic variants are predictive for severe hearing loss in children receiving cisplatin chemotherapy. Nature Genetics. 41, 1345 - 1349 Dec. 2009.

http://www.ncbi.nlm.nih.gov/pubmed/?term=Nature+Genetics (FA)

15. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross CJD, Aronica E, High KA, Levi MM, Hayden MR, Kastelein JJ, Kuivenhoven JA. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2303-4.
http://www.ncbi.nlm.nih.gov/pubmed/18802015 (CA)

16. Ross CJD, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR. Genotypic Approaches to Therapy in Children (GATC): A national active surveillance network to study the pharmacogenomics of severe adverse drug reactions in children. Annals of the New York Academy of Sciences. 1110:177-92. 2007.
http://www.ncbi.nlm.nih.gov/pubmed/17911433 (FA)

17. Ross CJD, Twisk J, Kuivenhoven JA, Rip J, Kastelein JJ, Hayden MR. Gene therapy with Lipoprotein Lipase Variant S447X. Arterioscler Thromb Vasc Biol. 2006;26:25-28.
http://www.ncbi.nlm.nih.gov/pubmed/16484602 (FA)

18. Ross CJD, Twisk J, Meulenberg JJM, Kuivenhoven JA, Miao F, Scheenhart-van der Meer JWC, Moraal E, Oranje PPA, Hermens WTJMC, Kastelein JJP, Hayden MR. Correction of Feline Lipoprotein Lipase Deficiency with AAV1-mediated gene transfer of the naturally-occurring LPLS447X beneficial mutation. Hum Gen Ther 2006;17(5):487-99.
http://www.ncbi.nlm.nih.gov/pubmed/16716106 (FA)

19. Ross CJD, Liu G, Kuivenhoven JA, Twisk J, Rip J, van Dop W, Ashbourne Excoffon KJ, Lewis SM, Kastelein JJ, Hayden MR. Complete Rescue of Lipoprotein Lipase-Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPLS447X Beneficial Mutation. Arterioscler. Thromb. Vasc. Biol. 25(10):2143-50. October 2005.
http://www.ncbi.nlm.nih.gov/pubmed/16002740 (FA)

20. Ross CJD, Twist J, Meulenberg JJM, Liu G, Van Den Oever K, Moraal E, Hermens WT, Rip J, Kastelein JJP, Kuivenhoven JA, Hayden MR. Long-term correction of murine Lipoprotein Lipase Deficiency with AAV1-mediated gene transfer of the naturally-occurring LPLS447X beneficial mutation. Human Gene Therapy, 15 (9) 906-919, September, 2004. (Cover)
http://www.ncbi.nlm.nih.gov/pubmed/15353045 (FA)

1. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2013 ;185(2):E115-20.
http://www.ncbi.nlm.nih.gov/pubmed/23209115

2. Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and Risk for Inflammatory Bowel Disease: A Nested Case-Control Study and Meta-analysis of Published and Unpublished Data. JAMA Dermatol 2013;149:216-20.
http://www.ncbi.nlm.nih.gov/pubmed/23426479

3. Bird ST, Hartzema AG, Etminan M, Brophy JM, Delaney JA. Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecol Endocrinol 2013
http://www.ncbi.nlm.nih.gov/pubmed/23311996

4. Bird ST, Delaney JA, Etminan M, Brophy JM, Hartzema AG. Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of Ethinyl-Estradiol? J Thromb Haemost 2013
http://www.ncbi.nlm.nih.gov/pubmed/23574590

5. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: A systematic review and meta-analysis. Mov Disord 2013
http://www.ncbi.nlm.nih.gov/pubmed/23609436

6. Yang L, Etminan M, Mikelberg FS. Oral Fluoroquinolones and Risk of Glaucoma. J Glaucoma 2013
http://www.ncbi.nlm.nih.gov/pubmed/23632400

7. Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5-alpha reductase inhibitors, finasteride and dutasteride. J Urol 2013;190:1811-4.
http://www.ncbi.nlm.nih.gov/pubmed/23665270

8. Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ 2013;185:475-82.
http://www.ncbi.nlm.nih.gov/pubmed/23734036

9. Pakzad-Vaezi KL, Etminan M, Mikelberg FS. The Association between Cataract Surgery and Atypical Antipsychotic Use: A Nested Case-Control Study. Am J Ophthalmol 2013
http://www.ncbi.nlm.nih.gov/pubmed/24075430

10. Forooghian F, Maberley D, Albiani DA, Kirker AW, Merkur AB, Etminan M. Uveitis Risk following Oral Fluoroquinolone Therapy: A Nested Case-control Study. Ocul Immunol Inflamm 2013;21:390-3.
http://www.ncbi.nlm.nih.gov/pubmed/23876164

11. Nathoo NA, Etminan M, Mikelberg FS. Association Between Glaucoma, Glaucoma Therapies, and Erectile Dysfunction. J Glaucoma 2013
http://www.ncbi.nlm.nih.gov/pubmed/23872619

12. Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ 2013
http://www.ncbi.nlm.nih.gov/pubmed/24192967

Faculty and Staff

Faculty:

Visiting Scientists:

  • Mara Medeiros, MD, PhD (Carleton) – (Visiting Scientist from Mexico)
  • Stan Bardal, BSc (Pharm), MBA, PhD (Carleton) – (Visiting Scientist from Victoria)

Trainees:

  • Kaarina Kowalec (Carleton) – Graduate student
  • Jennifer Park (Goldman) - Graduate Student (Paediatric Dentistry)
  • Neal Nasiboulin (Ross, Carleton) – Graduate student
  • Dr. Amit Bhavsar (Ross) – Research Associate
  • Dr. Britt Drogemoller (Ross, Carleton) – Postdoctoral Fellow
  • Shawna Galley (Carleton) - Graduate Student

Former Trainees:

  • Ricardo Jimenez (Carleton) - Post Doctoral Fellow
    Currently working in the Pharmaceutical Industry
  • Benji Heran (Carleton) - Post Doctoral Fellow
    Currently working as a research coordinator at UBC
  • Leah Mwai (Carleton) - Post Doctoral Fellow
    Currently pursuing another Post Doctoral Fellowship at the BC Centre for Disease Control
  • Ursula Amstutz (Carleton) - Post doctoral
    Currently an investigator at the Inselspital (University Hospital of Bern in Switzerland)
  • Kaitlyn Shaw (Carleton) - M.Sc. program
    Currently working as a clinical research coordinator at UBC
  • Tingting Zhang (Carleton) - Ph.D. program
    Currently pursuing a Post Doctoral Fellowship at UBC
  • Amy Chan (Goldman) - Graduate Student
  • Meghan Gilley (Goldman) - Department of Paediatrics
  • Michelle Sherwood (Goldman) - Department of Paediatrics
  • Adela Matejcek (Goldman) - Department of Paediatrics
  • Kelli Sherlock (Goldman) - Department of Paediatrics
  • John Lee (Ross) - Graduate 
  • Currently attending Medical School at UBC